KAREL helps patients and clinicians share and manage behaviour change, empowering them to take control of disease progression and end the need for dialysis and kidney transplants.
Current Status
- During our market and clinical research, we seeded a market before we even had a product - Product is now LIVE in app stores worldwide for patients - 20 future pilot hospitals and patient app users in 30 countries
Market
Core customer segments
Clinicians - Kidney doctors, nurse, and hospitals
Patients - From early-stage all the way through to dialysis. In our key markets of USA, UK, Canada, Australia, and NZ there are millions of patients
Partners - A mix of different pharma, insurance, and private health partners we are speaking to
Problem or Opportunity
Clinicians struggle to deliver the care kidney patients need
Solution (product or service)
Meet KAREL A one-stop-shop, remote monitoring solution for Kidney disease
Helping patients easily take control of their CKD journey with tools to manage their everyday life with an app.
Empowering clinicians with a 360 view of the patient experience to deliver high-quality online care outside of the clinic.
Competitors
Renalmate (US focused) > https://renalmate.com/ PatientMpower (also focus on Lung Disease) > https://info.patientmpower.com/ Current Health (disease agnostic) > https://currenthealth.com/
Advantages or differentiators
Renalmate > https://renalmate.com/ - Advantage - Pivoted from lifestyle wellness into kidney health so has experience in behaviour change of patients - Disadvantages - Their business model will struggle in public health markets outside the USA which KAREL has a strong focus
PatientMpower > https://info.patientmpower.com/ - Advantage - A few years ahead of our team and already embedded in a few hospitals across Europe (specifically Ireland) - Disadvantage - Have pivoted into Lung Health making their proposition less enticing for kidney patients
Current Health > https://currenthealth.com/ - Advantage - Strong investment to date with a very robust team of 40+ people - Disadvantage - As their platform is disease agnostic it will be less competitive in response to Kidney Health needs
Finance
Business model: SaaS to providers & Freemium to patients We charge hospitals $10 per patient per month to retain our remote monitoring software.
Go to market & revenue streams Patients: Freemium revenue
Pharma Research content Clinical trials SaaS/Revenue share
Money will be spent on
Patient community - scaling of app product (20%) Clinical trials - in partnership with hospitals (10%) IoHT & integration / product roadmap - (60%) Governance - ensuring our healthtech software is top tier in security (10%)
Offer for investor
Our mission is to stop CKD patients ever needing dialysis or transplants.
And with your help, we can make it happen.
Invest in helping people Chronic kidney disease is one of the fastest-growing health problems in the world Globally, CKD is projected to be the fifth most common cause of mortality by 2040. Now is the time to get ahead of the curve. And KAREL is looking for investment partners who want to make it happen.
Join us on our mission to take on this silent killer. In the process, we’ll save healthcare systems some of the $130 billion spent each year on CKD by empowering hundreds of millions of patients around the world through self-managed care.
